Unable to secure a profit in immunizing poorer nations, Western multinationals, including Oxford’s private partner AstraZeneca, have prioritized those who can pay the most. (By: Alan Macleod, Mintpress News) Europe is reeling from the shock ...
To make matter worse, Remdesivir is a drug that “has had its development costs paid for, in large part, by independent donors like governments and ministries of health in China, the WHO, and the US government.” ...